BIOMARKER:

RAD51D mutation

Entrez ID:

RAD51D mutation RAD51D mutation	Prostate Cancer Prostate Cancer	RAD51D mutation RAD51D mutation	Prostate Cancer Prostate Cancer	olaparib Sensitive: A2 - Guideline	olaparib Sensitive: A2 - Guideline
RAD51D mutation RAD51D mutation	Ovarian Cancer Ovarian Cancer	RAD51D mutation RAD51D mutation	Ovarian Cancer Ovarian Cancer	rucaparib Sensitive: B - Late Trials	rucaparib Sensitive: B - Late Trials
RAD51D mutation RAD51D mutation	Ovarian Cancer Ovarian Cancer	RAD51D mutation RAD51D mutation	Ovarian Cancer Ovarian Cancer	olaparib Sensitive: B - Late Trials	olaparib Sensitive: B - Late Trials
RAD51D mutation RAD51D mutation	Small Cell Lung Cancer Small Cell Lung Cancer	RAD51D mutation RAD51D mutation	Small Cell Lung Cancer Small Cell Lung Cancer	olaparib Sensitive: C2 – Inclusion Criteria	olaparib Sensitive: C2 – Inclusion Criteria
RAD51D mutation RAD51D mutation	HER2 Negative Breast Cancer HER2 Negative Breast Cancer	RAD51D mutation RAD51D mutation	HER2 Negative Breast Cancer HER2 Negative Breast Cancer	durvalumab Sensitive: C2 – Inclusion Criteria	durvalumab Sensitive: C2 – Inclusion Criteria
RAD51D mutation RAD51D mutation	Breast Cancer Breast Cancer	RAD51D mutation RAD51D mutation	Breast Cancer Breast Cancer	olaparib Sensitive: C3 – Early Trials	olaparib Sensitive: C3 – Early Trials

Associations